ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan

ADMA BIOLOGICS, INC.

$125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.
Total 2026 share repurchase initiative target is ~$200M, funded via existing $225M revolving credit facility.
Since program authorization in May 2025, ~$160M of common stock repurchased to date.
CEO states stock is "meaningfully undervalued" relative to business strength and growth trajectory.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.